miércoles, 1 de marzo de 2023

WORLD LYMPHEDEMA DAY 2023 – AWARENESS CAMPAIGN - Lymphatic Circulatory System Disease - Pediatric and Primary Lymphedema – Secondary Lymphedema – Lymphostatic Elephantiasis - Lymphatic Filariasis/Podoconiosis - Best Practices Management Guideline /Treatment Protocol/Patient Care Pathway - Awareness Campaign


Despite the existence of effective treatment, lymphoedema remains one of the world's most neglected diseases, and people affected in many countries are denied the basic human right to healthcare and are discriminated against. The burden associated with Stage III lymphoedema (elephantiasis) affects the physical, psychological, social, and economic well-being of those affected, contributing to the cycle of disability, disfigurement (bodily deformities), social stigmatization, poverty, and suffering of individuals.

Education and improving access to health services are keys to the successful prevention of Stage III Lymphedema (elephantiasis). The First-line edema volume reduction strategy for patients with established lymphedema is Complete Decongestive Therapy (CDT). Manual Lymphatic Drainage (MLD) and "Compression Garments" are the cornerstones of therapy. 

With reference to dermatolymphangioadenitis (DLA), also known as Infectious Cellulitis, studies have found that the control of swelling is associated with a lower risk of cellulitis, and that advanced stages of chronic edema are a strong risk factor. Evidence also supports that "Compression Garments" are essential. Infectious cellulitis can lead to sepsis (septicemia). Read more about what are the preventive measures for Infectious Cellulitis in lymphedema HERE.

This commemorative date serves as an opportunity for associative movements to make demands for people living with this disease. Some of the demands that the AGL Lymphedema Association is making are: The implementation of Complex Decongestive Therapy (CDT) with Manual Lymphatic Drainage for people diagnosed with lymphoedema in the public health system; early diagnosis, the need for more specialized professionals; the existence of a database with the real number of people affected by lymphoedema; as well as the creation of Lymphedema Reference Centres. Read more about which country has the best public health coverage of lymphoedema HERE.



IMPORTANT NOTICE 

Lymphedema is a serious chronic and progressive disease due to an organic disability. The clinical treatment of lymphedema is neither a cosmetic nor an aesthetic treatment. The treatment of lymphedema is to control its progression and alleviate the symptoms related to dysfunction of the lymphatic circulatory system. To prevent and avoid serious complications associated with treatment, such as the possible displacement of edema to previously unaffected areas when compression therapy is applied for volume reduction, patients should use highly specialized and experienced therapists. 

Professional qualification and instruction delivered remotely online are not the same as live hands-on practical instruction in the clinical training and certification of lymphedema therapists, similar to all other rehabilitation, medical, and surgical training programs, and especially for developing the necessary manual skills to treat a disease as complex as lymphedema. 

Patients should also take special care when choosing a "Multidisciplinary Center of Reference for Lymphedema", as not all countries and centers provide the same treatment options. The best choice is a center of reference that provides “Complete Decongestive Therapy (CDT)”, which is recognized as the “Gold Standard” treatment for lymphedema.

  • Read more about what is the best treatment option for Lymphedema HERE.
  • Read about what are the principal functions of Manual Lymphatic Drainage HERE.
  • Read about what are the main differences between the two principal lymphedema treatment protocols HERE. 
  • Read about what are the strategies for the implementation of low-cost treatment options for Lymphedema HERE.

REFERENCES

(Click on the texts to read the research articles)

SCIENTIFIC SOCIETIES

PATHOPHYSIOLOGY

CUTANEOUS COMPLICATIONS
INFECTIOUS COMPLICATIONS
CELLULITIS / DERMATOLYMPHANGIOADENITIS
TUMOURS

TREATMENT

COMPRESSION GARMENTS

DISABILITY

DISFIGUREMENT

PSYCHOSOCIAL IMPACT

PEDIATRIC LYMPHEDEMA

LYMPHATIC FILARIASIS / PODOCONIOSIS







Print this post